Two new biomedical upstarts are raising funds through IPO, with a total scale of 156 million US dollars!

Source: chuangjianhui 2018-03-29 recently, two potential biomedical new upstarts announced that they would be listed on NASDAQ as soon as possible after the establishment time was less than 2-3 years They plan to raise an overall scale of US $156 million, as follows: surface oncology: security code "surf", IPO Financing Target of US $75 million; mereo Biopharma: security code "mph", IPO Financing Target of US $81 million; surface oncology, located in Cambridge, Massachusetts, USA, was founded in 2014 and obtained investment from well-known investment institutions and large pharmaceutical companies, including atlas, Amgen ventures, Lily ventures, f-prime, New enterprise associates, etc., and attracted Dr Detlev biniszkiewicz, former AstraZeneca executive, to join as CEO The goal is to become the leader of the next generation of anti-cancer immunotherapy The idea of surface research and development is to focus on finding new targets in immune microenvironment regulation signals and developing new drugs to activate anti-cancer immunity Just in February, it launched its first clinical project, srf231, a candidate new drug targeting CD47 Another new drug targeting CD73 is also being declared for clinical application, and clinical trials are expected to start within this year Other preclinical pipeline products include CD39 inhibitor srf617 and IL-27 inhibitor srf388, which will be actively promoted to clinical development this year Surface's cancer immunotherapy R & D pipeline (photo source: surface official website) is different from the surface's own R & D pipeline Another new cutting-edge mereo biopharma from the UK was founded in 2015 In, we signed a cooperative development license with a large pharmaceutical enterprise, obtained the license of new drug project directly from the large pharmaceutical enterprise, and paid a certain license fee according to the development schedule Among the new drugs that have obtained the development license, the following are worthy of attention: azd9668, a neutrophil elastase inhibitor from AstraZeneca, is used to treat the alpha-1 antitrypsin deficiency (AATD) which is prone to occur in the lungs and liver, for which mereo has paid US $3 million in advance and US $2 million in equity to AstraZeneca; In addition, there is a leflutrozole (bgs-649) developed in cooperation with Novartis for the treatment of hypogonadotropic hypofunction in obese men, which has obtained positive phase 2 clinical data After 24 weeks of treatment, 75% of the patients' testosterone levels returned to normal Mereo biopharma's cancer immunotherapy R & D pipeline (photo source: mereo biopharma official website) has brought two completely different innovative drug development models, which are also favored by investors and attracted huge capital forces to promote the development of innovative drugs and accelerate the realization of the ultimate goal of benefiting patients.